CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Soochow University

Status and phase: Completed; Phase 2

Conditions: Acute Myeloid Leukemia, Relapsed, Adult

Treatments: Drug: CDIAG regimen

Study type: Interventional

Funder types: Other

Identifiers

NCT03985007

SZCDIAG

Details and patient eligibility

About

This study is to investigate the therapeutic efficacy and side effect of chidamide, decitabine combined with priming IAG regimen for relapsed or refractroy acute myeloid leukemia

Enrollment: 40 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Relapsed or refractory acute myeloid leukemia patients without severe complications such as active infections and bleedings; ECOG score less than 3.

Exclusion criteria

• Inablity to tolerate inducton chemotherapy; life expectancy less than 1 month

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

CDIAG

Experimental group

Description:

Relapsed or refractroy acute myeloid leukemia patients reveive chidamide, decitabine combined with priming IAG regimen treatment.

Treatment:

Drug: CDIAG regimen